Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50

REGENERON PHARMACEUTICALS, INC.

2022-FY EPS reported $38.22 revenue$12,172,900,000

Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.
GAAP diluted EPS $10.50 (Q4) and $38.22 (FY); non-GAAP $12.56 (Q4) and $44.98 (FY).
EYLEA U.S. net sales $1.50B Q4 (-3%), FY $6.26B (+8%); Dupixent global net sales $2.45B Q4 (+38%), FY $8.68B (+40%).
Aflibercept 8 mg BLA submitted for wet AMD/DME in Dec 2022; FDA approved Libtayo+chemo for NSCLC; EC approved Dupixent for prurigo nodularis and EoE.
New $3.0B share repurchase program authorized Jan 2023; FY2023 guidance: non-GAAP R&D $3.725-3.925B, non-GAAP SG&A $2.130-2.280B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENERON PHARMACEUTICALS, INC. reported Fourth Quarter 2022 results: revenue $3,414 million, net income $1,197 million, EPS $10.50.

Period: Fourth Quarter 2022
Revenue: $3,414 million
Net income: $1,197 million
EPS: $10.50
Result: reported results

Exact text from the filing

99.1 Document Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results • Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV ® and Ronapreve TM (a)(b) , revenues increased 14% • Full year 2022 revenues decreased 24% to $12.17 billion versus full year

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.